24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS Annual Meeting of the British-Society-for-Rheumatology and British-Health-Professionals-in-Rheumatology Taylor, P., Genovese, M., Keystone, E. C., Drescher, E., Berclaz, P., Lee, C., Fidelus-Gort, R., Schlichting, D., Beattie, S., Luchi, M., Macias, W. OXFORD UNIV PRESS. 2013: 44–45

View details for Web of Science ID 000318569000138